A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
G Shouse, A Kaempf, MJ Gordon, A Artz… - Blood …, 2023 - ashpublications.org
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
[HTML][HTML] A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
G Shouse, A Kaempf, MJ Gordon, A Artz, D Yashar… - Blood Advances, 2023 - Elsevier
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma.
G Shouse, A Kaempf, MJ Gordon, AS Artz… - Blood …, 2023 - europepmc.org
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
G Shouse, A Kaempf, MJ Gordon, A Artz… - Blood …, 2023 - ohiostate.elsevierpure.com
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
G Shouse, A Kaempf, MJ Gordon… - Blood …, 2023 - mdanderson.elsevierpure.com
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
G Shouse, A Kaempf, MJ Gordon, A Artz… - Blood …, 2023 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
[HTML][HTML] A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
G Shouse, A Kaempf, MJ Gordon, A Artz… - Blood …, 2023 - ncbi.nlm.nih.gov
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
G Shouse, A Kaempf, MJ Gordon, A Artz… - Blood …, 2023 - providence.elsevierpure.com
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
G Shouse, A Kaempf, MJ Gordon, A Artz… - Blood …, 2023 - scholars.northwestern.edu
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma.
G Shouse, A Kaempf, MJ Gordon, AS Artz… - Blood …, 2023 - digitalcommons.providence.org
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …
relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of …